Cadila Healthcare shines on getting USFDA’s nod for Aripiprazole Orally Disintegrating Tablets

31 Jul 2012 Evaluate

Cadila Healthcare is currently trading at Rs. 877.00, up by 7.05 points or 0.81% from its previous closing of Rs. 869.95 on the BSE.

The scrip opened at Rs. 865.00 and has touched a high and low of Rs. 890.05 and Rs. 861.75 respectively. So far 4495 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 905.00 on 19-Jul-2012 and a 52 week low of Rs. 629.00 on 25-Jan-2012.

Last one week high and low of the scrip stood at Rs. 890.05 and Rs. 847.00 respectively. The current market cap of the company is Rs. 18079.29 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 16.51% and 8.70% respectively.  

Zydus Cadila, an innovative global pharmaceutical company, has received tentative approval from USFDA for Aripiprazole Orally Disintegrating Tablets in the strengths of 10 mg, 15 mg, 20 mg and 30 mg. The drug is an anti-phychotic medication used in the treatment of schizophrenia.

Recently, the company entered into a settlement and license agreement with Somaxon Pharmaceuticals, and ProCom One to resolve pending patent litigation involving Silenor (Doxepin) 3 mg and 6 mg tablets.

Flagship company of Zydus Cadila Group, it focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×